Literature DB >> 24513467

Relation of highly sensitive cardiac troponin T in hypertrophic cardiomyopathy to left ventricular mass and cardiovascular risk.

Gilbert Cramer1, Jeannette Bakker2, Frank Gommans3, Marc Brouwer3, Maurice Kurvers4, Michael Fouraux5, Freek Verheugt3, Marcel Kofflard4.   

Abstract

Elevated cardiac troponin can be seen in patients with left ventricular (LV) hypertrophy and in asymptomatic subjects with a high a priori risk of cardiovascular disease (CVD). In hypertrophic cardiomyopathy (HC) troponin can be detected as well, but little is known about the contribution of LV mass, on the one hand, and the long-term risk of CVD, on the other. In an observational single-center study of 62 patients with HC, without a history of CVD, we assessed the Framingham Heart 10-year risk score (FH10yrs), LV mass index (LVMI) using magnetic resonance imaging, and highly sensitive cardiac troponin T (hs-cTnT). Hs-cTnT (>3 ng/L) was detectable in 74% of patients (46 of 62). Hs-cTnT was elevated in 26% (16 of 62) of patients (ninety-ninth percentile reference limit of 14 ng/L or more). From 3 to 14 ng/L, patients were older, more often had hypertension, and the FH10yrs was higher. Hs-cTnT correlated positively with LVMI (p<0.001) and maximal wall thickness (p<0.001). In addition, LVMI and hypertension were independently associated with increasing hs-cTnT concentrations in linear regression. Using multivariate binary logistic regression, both LVMI and FH10yrs were independently associated with detectable hs-cTnT levels. In contrast, only LVMI was associated with elevated hs-cTnT levels. In conclusion, hs-cTnT was detectable in 3 quarters and elevated in a quarter of our patients with HC. Although detectable hs-cTnT is associated with both LV mass and CVD risk, elevated hs-cTnT relates to LV mass only. This indicates that hypertrophy more than the risk of CVD seems the most important drive for hs-cTnT to occur in these patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24513467     DOI: 10.1016/j.amjcard.2013.12.033

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Impact of the papillary muscles on cardiac magnetic resonance image analysis of important left ventricular parameters in hypertrophic cardiomyopathy.

Authors:  D H F Gommans; J Bakker; G E Cramer; F W A Verheugt; M A Brouwer; M J M Kofflard
Journal:  Neth Heart J       Date:  2016-05       Impact factor: 2.380

2.  Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy.

Authors:  Eiryu Sai; Kazunori Shimada; Takayuki Yokoyama; Makoto Hiki; Shuji Sato; Nozomi Hamasaki; Masaki Maruyama; Ryoko Morimoto; Tetsuro Miyazaki; Shinichiro Fujimoto; Yoshifumi Tamura; Shigeki Aoki; Hirotaka Watada; Ryuzo Kawamori; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2016-05-03       Impact factor: 2.037

3.  Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy.

Authors:  Tanja Skyttä; Suvi Tuohinen; Eeva Boman; Vesa Virtanen; Pekka Raatikainen; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Radiat Oncol       Date:  2015-07-10       Impact factor: 3.481

4.  Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease.

Authors:  Christian Tanislav; Dursun Guenduez; Christoph Liebetrau; Anne Kathrin Giese; Sabrina Eichler; Nicole Sieweke; Maria Speth; Timm Bauer; Christian Hamm; Arndt Rolfs
Journal:  PLoS One       Date:  2016-06-20       Impact factor: 3.240

5.  Role of cardiac magnetic resonance in differentiating between acute coronary syndrome and apical hypertrophic cardiomyopathy.

Authors:  Renata Rajtar-Salwa; Paweł Petkow-Dimitrow; Tomasz Miszalski-Jamka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-11-17       Impact factor: 1.426

6.  High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  D H Frank Gommans; G Etienne Cramer; Jeannette Bakker; Hendrik-Jan Dieker; Michelle Michels; Michael A Fouraux; Carlo L M Marcelis; Freek W A Verheugt; Janneke Timmermans; Marc A Brouwer; Marcel J M Kofflard
Journal:  Int J Cardiovasc Imaging       Date:  2017-10-23       Impact factor: 2.357

7.  The diagnostic role of cardiac magnetic resonance used "first and last time in life" in a patient with a suspected dilated phase of hypertrophic cardiomyopathy.

Authors:  Rafał Hładij; Renata Rajtar-Salwa; Artur Dziewierz; Paweł Petkow-Dimitrow
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-05-30       Impact factor: 1.426

Review 8.  Implications of the complex biology and micro-environment of cardiac sarcomeres in the use of high affinity troponin antibodies as serum biomarkers for cardiac disorders.

Authors:  Christopher R Solaro; R John Solaro
Journal:  J Mol Cell Cardiol       Date:  2020-05-19       Impact factor: 5.000

9.  Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Changlin Zhang; Rong Liu; Jiansong Yuan; Jingang Cui; Fenghuan Hu; Weixian Yang; Yan Zhang; Youzhou Chen; Shubin Qiao
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

10.  High expression of FABP4 and FABP6 in patients with colorectal cancer.

Authors:  Yaqin Zhang; Xiaotong Zhao; Lili Deng; Xueting Li; Ganbiao Wang; Yongxing Li; Mingwei Chen
Journal:  World J Surg Oncol       Date:  2019-10-24       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.